A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer
This is a study of the safety and efficacy of MK-1775 in combination with paclitaxel + carboplatin in the treatment of ovarian, fallopian tube, and primary peritoneal tumours with the P53 mutation. In Part 1, a small group of participants will receive MK-1775 along with paclitaxel and carboplatin to find the maximum tolerable MK-1775 dose for this combination. Pharmacokinetics will also be assessed during this period. In Part 2, participants will be randomly assigned to receive either MK-1775 + paclitaxel + carboplatin or placebo + paclitaxel + carboplatin.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society